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Abstract: The hepatitis C virus (HCV) causes both acute and chronic infection and continues to
be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent
reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic
nature of acute infection can result in individuals not receiving treatment and unknowingly spreading
HCV. A prophylactic vaccine is therefore needed to control this virus. Thirty years since the discovery
of HCV, there have been major gains in understanding the molecular biology and elucidating the
immunological mechanisms that underpin spontaneous viral clearance, aiding rational vaccine design.
This review discusses the challenges facing HCV vaccine design and the most recent and promising
candidates being investigated.
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1. Introduction
First discovered in 1989 [1], the hepatitis C virus (HCV) is a major global health burden. Current
estimates of HCV prevalence state that approximately 1% of the world’s population are infected [2].
Chronic infection with HCV leads to cirrhosis of the liver and is associated with the development of
hepatocellular carcinoma (HCC). Annually, 400,000 deaths are attributed to HCV and in the US, deaths
from HCV have now overtaken those attributed to the human immunodeficiency virus (HIV) [3].
The extensive damage resulting from chronic infection makes this virus the leading cause for liver
transplantation, a procedure that ultimately results in reinfection of the transplanted organ [4,5].
In recent years, the growing problem of HCV prompted the World Health Organisation to set a target
to eliminate HCV as a public health burden by 2030. However, in the absence of a vaccine against
HCV, this will prove challenging.
Therapeutic treatment of HCV has been vastly improved over the past decade due to the
development of direct acting antivirals (DAAs). These compounds act as inhibitors of either the
NS3/4a serine protease, NS5a or the NS5b RNA-dependent polymerase [6] and can achieve a 95% cure
rate [7]. However, there are limitations to this strategy. Firstly, in order to treat an infection, a diagnosis
must be made which may not occur in asymptomatic cases. It has recently been reported that the
diagnosis rate in 2014 in the United Kingdom was estimated at capturing less than half of infected
individuals [8]. Secondly, the cost of these therapeutics limits their use in developed countries, and
all but excludes their use in low and middle-income countries with high HCV burdens. Thirdly, the
ability of HCV to rapidly respond to selective pressures means that the emergence of DAA-resistant
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strains is a major risk [9,10]. Indeed, resistance-associated substitutions (RAS) have been detected in
circulating HCV strains in treatment naive patients [11,12]. One such example of a RAS that has been
reported in treatment-naïve patients is the C316 mutation which has been associated with resistance to
non-nucleotide NS5B inhibitors such as Nesbuvir [13]. Another example is the S282T RAS which is
associated with sofosbuvir resistance in vitro [14] although at the time of writing this polymorphism
is not prevalent in clinical cohorts. The risk of DAA-resistance is mitigated by using combinational
therapies of DAAs that target different HCV proteins.
The ability to effectively treat HCV infection has been a major achievement. However, there is
growing evidence that HCV can leave lasting impacts upon its host post infection. For example, during
infection extensive liver fibrosis can occur, which can persist for several years after viral clearance.
Furthermore, persistent hyperfunctional CD8+ T cell phenotype has been reported following successful
treatment with DAAs, suggesting continued immunological impairment [15]. There are also conflicting
reports about the risk of hepatocellular carcinoma after virus clearance [16,17]. Understanding the
long-term effects following virus clearance will take years more research as more data become available
from successful cases. However, it is now apparent that therapeutics alone are unlikely to achieve the
2030 elimination target and thus a vaccine is urgently needed.
Modelling based on viral kinetics in reinfected individuals with pre-existing immunity has shown
that transmission risk can be greatly reduced when an immune response occurs, despite detectable
virus RNA titres [18]. This is of particular importance when considering vaccination of people who
inject drugs, a high-risk group for HCV infection and reinfection. This suggests that a successful
vaccine could be used to reduce viral titres rather than inducing sterilising immunity. This is a key
point as it provides a realistic goal for HCV vaccine research.
2. Host Immune Responses to Hepatitis C Virus
Virus-host interactions determine the outcome of acute HCV infection. This interplay is complex
and includes components of both the adaptive and innate host immune system. The most common
scenario is progression to chronic infection. However, 25%–40% of individuals undergo spontaneous
viral clearance (SVC) [19,20] within 12 months of infection [21,22]. Approximately 80% of these
individuals will achieve SVC a second time following reinfection [23] with a marked decrease in viral
RNA titres and reduced infection times compared to the first infection [23,24]. This indicates that initial
infection can lead to the establishment of an immunological memory which can control subsequent
HCV infection. This protective response consists of both humoral and cellular adaptive immune
responses that do not result in sterilising immunity but prevent chronic infection. This phenomenon
provides a benchmark for HCV vaccine research and thus is vital to elucidate.
2.1. Innate Immune Reponses
Innate immunity provides a first line of defence against viral infection. The liver presents a unique
microenvironment that is enriched with cells that participate in this response, namely Kupffer cells,
natural killer (NK) cells, hepatic stellate cells (HSCs) and macrophages. Initial innate responses are
triggered by HCV-derived pathogen-associated molecular patterns (PAMPs) that are recognised by
pattern recognition receptors (PRRs). Virion-associated PAMPs are the E1 and E2 glycoproteins [25,26],
while intracellular detection of viral PAMPs, including viral proteins and RNA, is mediated by toll-like
receptors (TLRs), nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) and retinoic
acid-inducible gene-I-like receptors (RLRs) [27,28]. Activation of signalling cascades downstream
of these receptors results in the production of proinflammatory cytokines including interleukin-1β
(IL-1β), IL-18 and type I and type III interferons (IFNs). These IFNs mediate upregulation of interferon
stimulated genes (ISGs) in an autocrine and paracrine manner leading to an antiviral response in the
liver [29,30]. However, the HCV viral proteins core, E2, NS3/4a and NS5a all impair the expression
of ISGs through disruption of signalling cascades, allowing the virus to overcome the host innate
response [31,32]. This results in an innate immune response that is incapable of clearing HCV.
Vaccines 2020, 8, 90 3 of 23
Successful SVC is influenced by the outcome of innate immune responses. A major example
is the association of single nucleotide polymorphisms (SNP) rs12979860 present in the type III IFN
gene IFNλ4 with SVC. In this case approximately 50% of individuals with a C/C genotype achieve
SVC [33,34]. Additionally, NK inhibitory receptor, killer immunoglobulin receptor 2DL3 (KIR2DL3)
and human leukocyte antigen C group 1 (HLA-C1) are associated with SVC [35] due to a reduced
inhibition of cytotoxic NK activity [36,37].
2.2. Ceullar Immune Responses
Cellular immunity has long been associated with spontaneous HCV clearance [38] and is mediated
through two main T cell subsets, the cytolytic CD8+ T cells and CD4+ helper T cells. CD8+ T cells
destroy infected cells in a manner restricted by MHCI presented epitopes [39]. In contrast, recognition
by CD4+ helper T cells is MHCII restricted and their role is to aid the function of CD8+ T cells and the
establishment of T cell memory through the secretion of cytokines such as IFN-γ [40,41]. CD4+ T cells
also aid B cell activation and a CD4+ T cell subset, follicular helper T cells (TFH) are required to establish
a long-term antibody response [42,43]. HCV-specific T cells are detectable within the first 12 weeks
of infection and target a broad range of HCV epitopes present on both structural and non-structural
viral proteins [44]. During the progression to chronicity, the HCV-specific CD4+ T cells display an
exhausted phenotype and the population collapses [45,46]. The decrease in CD4+ T cell function leads
to a dysregulated CD8+ T cell response in which these cells become exhausted and dysfunctional
with reports of continued IFN-γ secretion but an absence of cytolytic activity [47]. The reasons for
this reduction in effective cellular responses are incompletely understood. The loss of functional
HCV-specific T cells could be the result of host regulation of the immune system since persistent
antigen stimulation could lead to the prolonged production of proinflammatory cytokines which in
turn contributes to hepatic tissue damage.
The importance of T cells to SVC was first demonstrated in experimentally infected chimpanzee in
which HCV persistence was observed in the absence of either a CD4+ or CD8+ T cell response [48,49].
Interestingly, when CD4+ T cells were depleted HCV persisted alongside functional CD8+ T cell
responses. HCV-specific CD4+ T cells and CD8+ T cells are detectable during acute infection [45]. This
provides strong evidence that the T cell responses have a major role in the outcome of HCV infection.
HCV-specific CD4+ T cells are broadly targeting with the most common epitopes being found in the
core, E2, NS3, NS4a, NS4b, NS5a and NS5b HCV proteins [44].
2.3. Humoral Immune Responses
Neutralising antibodies (nAbs) in the context of HCV infection were first described by
Farci et al. [50], although their role in spontaneous clearance was disputed for many years due
to reports of cell mediated clearance in seronegative individuals [51–53], suggesting that nAbs are not
essential to achieve SVC. However, analysis of sera from individuals who cleared HCV has shown
the presence of nAbs and these are detectable at earlier time points compared to acute infections that
proceed to chronicity and are subsequently lost following viral clearance [54] suggesting that a rapid,
short-lived humoral response is required for clearance [55–58]. It has recently been shown that nAbs
generated within the first 100 days of infection often have a narrow neutralising capacity directed
towards the founder virus [58]. The selective pressure exerted by nAbs upon the circulating strains can
also drive the evolution of HCV towards escape mutations that compromise viral fitness further aiding
clearance of the infection [59,60]. The delayed appearance of cross-reactive nAb responses are apparent
in chronically infected individuals as isolated sera can neutralise circulating strains from previous
infection time points with greater potency than the current dominant virus [56] and cross-reactive nAbs
have been isolated from chronically infected individuals [61–64]. Although these nAbs cannot clear
the infection, they have been associated with reduced liver fibrosis [65] and patients that experience
hypogammaglobulinemia have a more severe disease progression [66].
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Further insight into the humoral response has been obtained through characterising nAbs derived
from patients. Bailey et al. [67] sequenced cross-reactive nAbs isolated from two individuals that
cleared HCV and showed these nAbs shared >90% similarity with germline heavy chain variable
(VH) genes and >92% similarity with germline light chain gene sequences revealing that generation of
cross-reactive nAbs required limited somatic hypermutation. A common feature of these nAbs was
the VH1-69 gene which is found in potent cross-reactive nAbs that target antigenic region 3 (AR3)
and is also present in nAbs targeting HIV and Influenza [68–71]. Structural investigation has also
shown that cross-neutralising activity is a result of long complementarity-determining region H3
(CDRH3), typically 18–22 residues, that forms a β-hairpin structure that is stabilized by a disulphide
bond allowing for interaction with conserved E2 epitopes [72,73]. This level of insight into how potent
nAbs work can inform rational design of B-cell immunogens to favour the production of these types of
antibodies in the host.
3. Hepatitis C Virus Envelope Proteins as Vaccine Targets
The HCV envelope glycoproteins, E1 and E2, are located at residues 192–746 of the polyprotein
and are the targets of the humoral immune response, making them an attractive vaccine target [74]
(Figure 1A). Both E1 and E2 are type I transmembrane proteins that form an intracellular non-covalent
heterodimer that form higher order covalent structures on the mature virion [75,76]. The E2 ectodomain
contains an immunoglobulin-like β-sandwich that is flanked by α-helices which form a front and
back layer [77,78]. There are also regions that exhibit high levels of variability which are referred to as
hypervariable regions (HVRs) 1 and 2, and a third intergenotypic variable region (IgVR; Figure 1A).
The E1 protein is smaller, more conserved than E2 and less well characterized with partial crystal
structures resolved for fragments encompassing residues 192-271 [79] and 314–324 [80].
The E1E2 heterodimer mediates entry into the hepatocytes through interactions with four essential
host receptors, CD81 [81,82], scavenger receptor B1 (SRB1) [83], claudin [84] and occludin [85,86].
The first step in viral entry is the interaction between SRB1 and the HVR1 (Figure 1A) located at the
N-terminus of E2 which induces a conformational change that exposes the conserved E2 core region
and the CD81 binding loop (residues 519–535) [77]. The interaction between E2 and CD81 results
in recruitment of claudin to CD81 which leads to clathrin-mediated endocytosis [87]. Membrane
fusion occurs in low pH endosomes, which is thought to induce a conformational change in the E1E2
heterodimer [88]. This leads to membrane fusion, possibly mediated by E1 via the action of a putative
fusion peptide located at residues 272–285 (Figure 1A) [89].
Antibody-mediated neutralisation of HCV is achieved through targeting the E1E2 heterodimer
on the surface of the virus. To date, most characterized nAbs target the E2 protein. The are several
linear and discontinuous regions of E2 that are targeted by Abs and these have varying nomenclature,
being referred to as ARs1-5 [69], Epitopes I-III (Figure 1) [90], or domains A-E [91]. Importantly, AR4
and 5 are reliant on the presence of the E1E2 heterodimer for binding [69]. The epitope I, II and AR3
regions form the neutralising face of E2 which is targeted by some of the most potent cross-reactive
nAbs described to date [92] arguing for their inclusion in a nAb-eliciting vaccine.
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globally followed by Gt3 accounting for 17.9% of cases [96], and are more prevalent in developed 
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multiple subtypes. However, the recently reported Gt8 group currently contains a single subtype 
isolated from four individuals [97]. Rapid evolution of HCV during the course of an infection leads to 
the establishment of a heterogeneous population [98]. The diversification of this population is driven 
by host immune selective pressure and the degree to which variation occurs in acute infection correlates 
with a progression to chronicity [99]. 
Figure 1. (A) Schematic diagrams of the hepatitis C virus envelope glycoproteins E1 and E2, showing
N-linked glycosylation sites (N), transmembrane domains (TMDs), and the E1 fusion peptide (FP). E2
hypervariable regions (HVRs) 1 and 2, and the intergentypic variable region (IgVR) are also depicted.
Linear epitopes I, II and III are highlighted in red, dark blue and light blue, respectively. (B) E2 structure
(PDB: 6MEH). Linear epitopes I, II and III are highlighted in the corresponding schematic. Antigenic
regions (ARs) are also shown.
4. Challenges to Hepatitis C Virus Vaccine Design
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driven by host immune selective pressure nd the degree to which variation occurs in acute infectio
correlates with a progression to chronicity [99].
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The extent of genetic diversity gives rise to genotype-specific immune responses. The E1E2
sequence shows the greatest level of variation as a result of the selective pressure exerted by the
host immune response [100], leading to humoral responses that can have reduced heterologous
neutralising activity [101]. However, cross-reactive nAbs that are capable of targeting isolates from
different genotypes have been described in several studies [102], thus highlighting that this challenge
can be overcome. Epitope variability also leads to genotype-specific cellular responses for example
Luxenburger et al. [103] have recently shown CD8+ T cells from individuals chronically infected with
a Gt4 HCV isolate failed to recognize Gt1 derived epitopes. Limited intergenotypic cross-reactivity of
Gt3 HCV-specific T cells has also been reported in patients that successfully cleared Gt3 infections [104].
Limited cross-reactive immune responses to distantly related HCV isolates will be a key challenge to
produce an effective vaccine
4.2. Evading the Host Adaptive Immune Response
The ability of HCV to establish a chronic infection highlights the efficiency in which this
virus can subvert the host immune response. This is achieved through multiple strategies. Firstly,
immunodominant epitopes such as the HVR1 of E2 elicit a response of non-neutralising antibodies.
Currently it is thought that HVR1 acts as a shield of the more conserved epitopes in the E2
core that contain CD81 binding residues, since removal of HVR1 increases virus susceptibility
to neutralisation [105,106]. Evidence also shows that HVR1 induces greater homologous nAbs and
deletion induces broader heterologous nAbs [107].
Epitope masking is also achieved through the glycosylation of envelope proteins to form a glycan
shield [108]. This mechanism diminishes the binding of nAbs and is used by other viruses such as
HIV and Influenza although by comparison, HCV exhibits a reduced variability in the position of each
glycan group. The E1 and E2 proteins contain 4 and 11 N-linked glycosylation sites which are highly
conserved across different genotypes (Figure 1A) [109]. Deletion of E2 glycosylation sites increases
HCV susceptibility to nAbs showing that glycosylation acts via steric hinderance to nAbs [109,110].
Interestingly, removal of E2 glycan sites or expression of this protein in systems that use smaller, less
complex glycan groups enhance the immunogenicity compared to mammalian expressed E2 [111–113].
Another mechanism in which nAb resistance can be mediated through glycosylation is glycan shift.
This arises through non-synonymous mutations that result in the deletion of a glycosylation site and
the appearance of a new glycosylation site in a different position in the protein. Pantua et al. [114]
reported this phenomenon after incubating cell cultured HCV (HCVcc) with the murine nAb, AP33
which targets residues within the E2 epitope I region [115]. After 5 days of incubation with AP33,
escape mutants could be detected which contained either N417S or N417T residue variations coupled
with a new glycosylation site at position 415 [114].
The evasion of nAbs can also be attributed to the presence of host derived factors. One such factor
is high-density lipoproteins which are present in human serum and has been shown to increase HCV
infectivity via SR-BI interactions which in turn decreases the time available for nAbs to bind to their
target [116,117]. Additionally, the presence of host derived apolipoprotein E on the mature HCV virion
has been shown to have a role in epitope masking the E2 protein abrogating nAb activity [118]. Another
evasion method is through the use of decoys. Recently it has been reported that in a HCVcc system,
infected cells produce lipid droplets coated with the E2 protein [119]. This may also be a strategy to
subvert the immune system by using these E2-coated droplets to interact with nAbs, thereby reducing
the availability of nAbs to target E2 present on the surface of the virus particle. Finally, evasion
from nAbs has recently been shown to be associated with resistance to antiviral interferon-induced
transmembrane (IFITM) proteins [120] showing that the innate immune response can also be a driving
force for nAb evasion.
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4.3. Models for Hepatitis C Virus Infection
4.3.1. In Vitro Models
Since the discovery of HCV, research was hampered by the lack of infection models both in vivo
and in vitro. The use of models in vaccine research is essential for the assessment of sera and monoclonal
antibodies arising from natural infection, experimental immunizations or vaccine trials. In the case
of in vitro models, the key challenge was generating a cell culture-based system that could produce
infectious HCV at titres suitable for further experimentation. This problem was solved with the
discovery of two Gt2a isolates, JFH1 and J6 which produce high titres of infectious HCV from cultured
Huh 7.5 cells [121]. Following this, it was found that intergenotypic recombinant viruses consisting of
core-NS2 of an isolate of interest fused to NS3-NS5b of JFH-1 could produce viable chimeric viruses [121].
The developments in HCVcc techniques have allowed panels with representatives of the seven major
genotypes to be set up [122–124]. Our group has recently described a method in which E1E2 patient
derived sequences could be incorporated into chimeric HCVcc expression vectors [125,126], further
aiding the ability to characterize isolates that have different neutralisation phenotypes.
Viral pseudotyping has also been used to study the entry mechanism of HCV. This approach utilizes
the ability of retroviral gag/pol proteins to self-assemble into enveloped virus particles. Simultaneous
expression of foreign viral envelope proteins in the same cells leads to the incorporation on to the
surface of the retroviral particle whose entry properties are dictated by the envelope glycoprotein.
Infectivity can be measured by the incorporation of a reporter gene, usually luciferase, which is
introduced into target cells and expressed. Methods to generate HCV pseudoparticles (HCVpps)
commonly use murine leukemia virus or HIV derived vectors [127,128]. Our group and others have
utilized these systems to characterize extensive panels of patient-derived E1E2 sequences allowing
important characterisation of these unique isolates [57,129–131]. These studies have shown that
neutralisation sensitivity of patient derived isolates to both sera and monoclonal nAbs is markedly
varied and not associated with genotype but is isolate dependent. Furthermore, it has been shown
that the HCV reference isolate H77, a Gt1a isolate that was first adopted due to its ability to infect and
cause disease in chimpanzees [132–134], is more susceptible to antibody-mediated neutralisation than
many patient-derived isolates [102]. This finding is of significance since H77 neutralisation has been
used to validate multiple vaccine candidates and therefore these data provide limited insight into how
effective a candidate may be towards clinically relevant isolates. H77 has also been used in the design
of immunogens with moderate success, although it could be argued that immunogen design based on
more nAb-resistant isolates may elicit more potent nAbs.
The ability to generate both HCVcc and HCVpp provide essential tools for the in vitro study
of HCV and assessing the neutralising breadth of sera and monoclonal nAbs. The importance of
isolate panels for the validation of vaccine candidates is exemplified in the field of HIV vaccine
research, in which candidates have been tested against an extensive panel of 109 isolates developed by
Seaman et al. [135], which are grouped based on neutralisation susceptibility. In this way humoral
responses following vaccination can be assessed in a standardized manner allowing for relevant
comparisons between candidates and vaccines that induce responses capable of neutralising the most
resistant isolates can be identified for further development. At the time of writing a consensus panel of
isolates is yet to be widely adopted but doing so will greatly enhance our understanding of which
candidates are promising and those that are not.
4.3.2. In Vivo Models
Humans are the natural host of HCV, and therefore it is imperative that suitable in vivo models
are used in order to test the efficacy and safety of preclinical vaccine candidates. Arguably, the most
successful model has been the chimpanzee, which is permissive to HCV infection under experimental
conditions. However, ethical concerns over the use of this species has led to a ban on its use in
experimental research. An alternative has been the use of chimeric humanized or transgenic mouse
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models which have humanized livers such as Alb-uPA/SCID mice [136,137] or those engineered to
express human CD81 and occludin [138,139]. There are limitations to using chimeric mouse models,
most notably that they do not exhibit cirrhosis or HCC, and are technically difficult to produce [140].
In light of the limited options available for the in vivo modelling of HCV, there has been increasing
interest in other members of the Hepacivirus genus for use as analogues. At the time of writing there
are two species of particular interest, the Rodent Hepacivirus (RHV) and the Equine Hepacivirus
(EqHV). RHV was initially discovered in the species Rattus norvegicus in 2014 [141]. Experimental
infection of different lab rat breeds leads to the establishment of permanent infection with features
observed during HCV infection in humans such as hepatic fibrosis, steatosis and evidence of SVC in
the Holtzman rat strain [142]. There are key contrasts between RHV and HCV infections, notably the
lack of IFN-γ+ CD8+ T cell responses during RHV infection [143].
EqHV was initially discovered in canines and subsequent serology testing identified equines as
the natural host [144,145]. This virus is the closest relative of HCV and there are shared features of both
species such as similar levels of glycosylation of the E1E2 proteins and a conserved seed site in the
5′-UTR for the liver-specific microRNA-122 (miR-122) which contributes to stability, translation, and
replication of the viral RNA [146]. Seroprevalence of EqHV is in the region of 30% of surveyed horses,
with approximately 3% testing positive for viral RNA [147]. This discrepancy between serology and
viral RNA may be indicative of a high viral clearance rate. Despite this potential high clearance rate,
EqHV acute infection may proceed to chronicity after 6 months [148], further validating the relevancy
of this virus as a model for HCV.
The use of analogous Hepacivirus species will allow for the testing of vaccine strategies and the
experimental challenge in the natural host of that species, a feat that cannot currently be achieved
for HCV. Whilst these approaches are likely to prove highly valuable to the field of HCV vaccine
research it is important to acknowledge the differences in mammalian immune systems and how this
will impact on our interpretation of experimental data. For example, the IgVH 1-69 gene with an
extended CDRH3 region has previously been described as a feature of anti-HCV specific nAbs that
are elicited in SVC and therefore it is logical that a vaccine candidate could be assessed based on its
ability to elicit these types of nAbs. With this in mind it is worth considering how comparable the
antibodies of animal model species are to those of humans. One such difference is the length of the
CDRH3 regions which are typically 16 residues long [149], however these are reduced to an average
of 12 to 14 residues in rodent [149] and equine species [150], respectively. The CDRH3 region can be
critical for the formation of the antigen-antibody complex and extended CDRH3 loops are effective at
penetrating the glycan shield of viral envelope proteins, a favorable characteristic of anti-HCV nAbs.
This raises an important question about the relevance and suitability of current animal models as
predictors of the human antibody response. Similarly, the paradigm of vaccine research has been
to test novel candidates in small animals followed by larger animal species before clinical testing in
humans. This approach enables evaluation of immunogenicity and safety prior to exposure of an
immunogen in humans. However, questions should be asked as to whether this approach has hindered
the progress of at least some HCV vaccine candidates because of differences between the model and
human antibody repertoires.
4.4. Rational Design of Immunogens to Elicit Cross-Reactive Neutralising Antibodies
The informed, rational design of immunogens will be vital in order to produce a successful HCV
vaccine. As advances in the analysis of antibody repertoires are allowing deeper insight into the types
of nAbs that are associated with SVC, there is potential to use this information to develop immunogens
that favour the production of these types of antibodies. An example of this can be seen with the E2
epitope I region or antigenic site 412 (AS412). This linear epitope is structurally flexible and when
in complex with nAbs and adopts three distinct conformations. Firstly epitope I forms an extended
conformation in complex with the rat nAb 3/11, a β-hairpin conformation is observed when bound to
AP33 or the human nAb HCV-1, and an intermediate conformation occurs when in complex with the
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human nAb HC33.1 [151]. As previously discussed, HCV may escape epitope I targeting nAbs by the
mechanism of glycan shift. However, this mechanism does not abrogate and instead enhances the
potency of HC33.1 [152]. With this in mind, rational design of an immunogen could strive to present
the epitope I region in an intermediate conformation to bias the humoral response to elicit HC33.1-like
nAbs. To date this has not been investigated however, efforts have been undertaken to present epitope
I in the β-hairpin conformation using cyclic peptides based on θ-defensin which adopts a similar
conformation [153]. This approach induced nAb responses when tested in mice however these were
lower compared to mice immunized with E2 [153]. The rational design of HCV epitopes in this way
is technically challenging and is limited to targeting linear epitopes. Additionally, delivery of cyclic
peptides will require further development in order to enhance the immunogenicity and stimulate
greater titers of nAbs.
5. Vaccine Prospects
Despite the challenges faced in HCV vaccine design, there have been a variety of different vaccine
approaches investigated with a small number of these candidates reaching human trials (summarized
in Table 1). Currently, DNA and peptide-based vaccine candidates are actively being investigated in
murine models [154–158]. One recently reported peptide candidate consisted of overlapping peptides
derived from the p7 protein which induced antigen-specific CD4+ T cells and cytotoxic CD8+ T cells
capable of targeting p7 expressing hepatocytes in vivo [154]. This study has been the first to show the
immunogenicity of p7 when used as the sole target in a vaccine. Additionally, a DNA-based vaccine
has been shown to induce CD4+ T cell and CD8+ T cell responses and elicit T cell memory in mice;
however, a non-neutralising Ab response was also observed [156]. These vaccine candidates are in an
early stage of development and therefore the following sections will discuss candidates that have been
more extensively studied.
5.1. Recombinant Subunit Vaccines
Recombinant subunit vaccines are an attractive technology as they have previously been utilized
for a variety of pathogens [159] and are economical to produce on a commercial scale. In the field of
HCV vaccine research, attempts to generate a subunit vaccine have focused exclusively on targeting
the HCV E proteins. The most successful candidate has been the recombinant E1E2 protein (rE1E2)
derived from a Gt1a isolate. Initially, HCV-1 derived rE1E2 was used to vaccinate seven chimpanzees
which resulted in a humoral response [160]. Following homologous HCV challenge, five out of seven
vaccinated chimpanzees exhibited sterilising immunity with the remaining two developing acute
infections that were subsequently cleared [160,161]. This was further validated in small animal models
and that immunisation rE1E2 derived from a single isolate could induce cross-reactive nAbs [161].
Following this work, a phase I human trial was performed in which rE1E2 derived from the Gt1a
HCV-1 isolate was administered at different doses (4 µg, 20 µg and 100 µg of rE1E2) with the MF59
adjuvant to healthy volunteers [162]. Importantly this study showed that rE1E2 can be safely tolerated
in humans, a finding of significance given that a successful HCV vaccine candidate will likely require
these proteins or derivatives of them. Polyfunctional CD4+ T cell responses were detected and the
magnitude of this response was inversely related to dosage. Humoral responses and nAbs were initially
reported [162,163] and further testing using a diverse HCVcc panel with isolates from Gt1-7 showed
that 3/16 volunteers had elicited cross reactive nAbs [164]. Additionally, post vaccination sera from
5 volunteers competed with nAbs AP33, AR3B, AR4A, AR5A and IGH526, showing that the humoral
response targeted both E1, E2 and the E1E2 heterodimer [165]. The ability for rE1E2 from a single
isolate to induce nAbs in humans is significant and encouraging although work should be undertaken
to enhance the efficacy at which nAbs are generated. A key issue with rE1E2 was purification which
relied on lectin-based affinity methods that were low affinity and non-specific [166]. Furthermore,
efforts to improve rE1E2 production were made by removing the transmembrane domains of the E
protein. However, this truncated E1E2 was found to be a weak immunogen that elicited low levels of
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nAbs [167]. In light of these issues, both flag-tagged and Fc-tagged rE1E2 have been investigated and
elicit nAbs in mice at comparable levels to wild type rE1E2 [166,168].
Another subunit vaccine approach has been the use of truncated soluble E2 (sE2) which results
in a secreted form of the E2 ectodomain. A candidate of particular note is the H77 derived
sE2384-661 construct with deleted HVR1, HVR2 and IgVR (sE2∆123) which can be expressed in
a correct conformation which interacts with CD81 and conformation sensitive antibodies [169–171].
Vietheer et al. [170] reported that the expression of sE2∆123 in mammalian cells results in biochemically
and immunogenically distinct isoforms of this protein that exist as monomeric, dimeric, pentameric
and a high molecular weight aggregate (HMW1; estimated at 51 protomers). Immunisation of guinea
pigs with different isoforms showed that HMW1 elicited greater titres of cross-reactive nAbs that could
neutralise isolates from Gt2a, 4a, 5a, 6a and 7a expressed in a HVCcc system [170]. Additionally, HMW1
had exhibited a reduced activity with non-neutralising antibodies, suggesting that this aggregate
focuses the humoral immune response away from these epitopes, allowing for greater focusing to nAb
epitopes [170]. Whilst this initial report is promising, it was noted that sE2∆123 reduced homologous
neutralisation activity, a likely result of the removal of HVR1 which was also observed by Law and
colleagues [172].
5.2. Virus-Like Particles
Virus-like particles (VLPs) are a promising area of vaccine research and have been investigated
extensively to design a HCV vaccine [173]. To date, there are two widely used commercial vaccines
that utilize VLP technology, the hepatitis B virus (HBV) and human papilloma virus vaccines. VLPs
are formed when the structural proteins of a virus assemble in a genome-independent manner to
produce a particle that resembles the native virus whilst lacking the ability to replicate and are more
immunogenic than soluble protein due to their repetitive structure and ability to drain into tissue
lymph nodes [107,174].
HCV-LPs were first described by Baumert et al. [175] in which VLPs were expressed in the insect
cell line Sf9 following transduction with a recombinant baculovirus containing the core E1 and E2
HCV structural proteins. These HCV-LPs elicited HCV-specific IgG production, IFN-γ secreting CD8+
T cell and CD4+ T cell mediated cellular responses in mice and baboons [176–178]. Immunisation
of four chimpanzees with four doses of HCV-LPs resulted in CD4+ and CD8+ T cell responses in
all animals [179]. Subsequent challenge with homologous HCV resulted in a reduced viremia in
vaccinated animals compared to controls with two animals testing negative for HCV two years post
challenge [179]. Interestingly, humoral responses in chimpanzees were not detectable in three of
these animals and appear to have been absent during the reduction of viremia. Further work on this
candidate has not been progressed since this first study in chimpanzees. However, it is an important
example for future HCV vaccine work, as it showed that viral clearance can be achieved using an
experimental VLP vaccine candidate. Despite work on this candidate ceasing, HCV-LPs continued to be
investigated. Recently, a HCV-LP system has been established through the transduction of the human
hepatoma cell line Huh 7 with recombinant adenovirus encoding the structural genes of HCV [180].
Initially designed using the H77 isolate, further development has expanded by generating HCV-LPs
using the structural sequences of different isolates representing Gt1b, 2a and 3a subtypes to produce
HCV-LPs with a conformation close to that the wild type virus [180–183]. Trials of this candidate in
mice showed the induction of nAbs and activation of both CD4+ and CD8+ T cell responses and this
has recently been reported in a vaccinated Landrace pigs [184]. To date, assessment of the humoral
response has demonstrated that this vaccine elicits nAbs with activity towards homologous strains.
Heterologous neutralisation data have not been reported for this candidate. Testing the sera from
animals immunized with this quadrivalent vaccine against a diverse panel of HCV isolates would be
of particular interest not only for this candidate but to inform future vaccine design.
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5.3. Viral Vector Vaccines
Viral vectors have the capacity to induce high level cellular immune responses [185], making them
an attractive approach for HCV candidates. Viral vectors of particular interest are human adenovirus
6 (HuAd6), chimpanzees Ad 3 (ChAd3) and modified vaccinia ankara (MVA) [186]. The only HCV
vaccine candidates to be tested in phase I and phase I/II human trials has been ChAd3 and MVA which
each encoded HCV NS3, NS4a, NS4b, NS5a and inactivated NS5b (NSmut) derived from the Gt1b BK
isolate [187,188]. These candidates were tested together in a heterologous primer/boost strategy in
which healthy human volunteers were primed with ChAd3-NSmut and boosted with MVA-NSmut
8 weeks later [188]. The results of this phase I study showed that prime/boost ChAd3/MVA-NSmut
induced both CD4+ T cell and CD8+ T cell responses directed towards epitopes on all five HCV
non-structural proteins, importantly the effect of the MVA-NSmut enhanced the T cell responses
and these were detectable at week 70 [188]. Given the promising cellular responses observed in the
phase I trial, this approach was tested in patients with chronic HCV infections although this was
unable to reverse T cell exhaustion [189], ruling out the use of ChAd3/MVA-NSmut as a therapeutic
vaccine. Recently ChAd3/MVA-NSmut was tested in a large phase I/II trial involving 548 high risk
individuals was concluded (clinicaltrials.gov identifier: NCT01436357). At the time of writing, this
trial has concluded, and data have yet to be published. However, a press release statement from the
National Institute of Allergy and Infectious Disease stated that 14 vaccinated individuals became
chronically infected with HCV, suggesting that this candidate does not provide protection against HCV
infection [190]. Understanding the reasons for this failure will be vital to inform our understanding of
vaccine design. Given that the ChAd3/MVA-NSmut candidate exclusively targeted T-cell epitopes,
the failure of this vaccine candidate could further emphasize the need for both humoral and cellular
immune responses in clearance of acute infections.
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Table 1. Summary of recent hepatitis C virus vaccine candidates. Subunit, virus-like particle (VLP), viral vector, peptide and DNA vaccine approaches are listed with
the vaccine target, genotype (Gt) and isolate from which the candidate was derived, tested species and the humoral and cellular immune responses were reported.





HCV-1 rE1E2 E1E2 Gt1a HCV-1 humans homologous and heterologous yes N.D [162,164]
H77 sE2∆123 E2core Gt1a H77 guinea pigs homologous and heterologous N.D N.D [170]
Virus-Like particles
core, E1, E2 from Gt1a, 1b, 2a
and 3a core, E1, E2
Gt1a H77, Gt1b BK,
Gt2a JFH1, Gt3a mice, pigs homologous neutralising antibodies yes yes [181,184]
HBV/HCV-LPs E1, E2 Gt1a H77 rabbit
homologous, heterologous activity
towards Gt1a and 1b, reduced activity
towards Gt2a and 3a isolates.
N.D N.D [191]
HBV/HCV-LPs linear E1 and E2epitopes not stated mice heterologous towards Gt1a, 1b and 2a N.D N.D [192]
murine leukaemia
VLP-HCVE1E2 E1, E2 Gt1a H77 mice, macaques
homologous, heterologous towards Gt1b,
2a, 2b and 4c yes N.D [193]
Viral vector
ChAd3/MVA-Nsmut NS3, NS4a, NS4b,NS5a, NS5b Gt1a BK humans N/A yes yes [188]
Peptide
p7 p7 Gt1b J4 mice N/A yes yes [154]
HCVp6-MAP E1, E2, NS4b,NS5a, NS5b Gt4a ED43 mice homologous, heterologous towards JFH1 yes yes [155]
DNA
pVax-sE1E2-IMX313P E1, E2 Gt1b mice homologous, heterologous towards Gt1a,1b, 2a, 2b, 3a, 4a, 5, 6 yes N.D [158]
DREP-HCV/MVA-HCV core, E1, E1, p7,NS2, NS3 Gt1a H77 mice non-neutralising IgG yes yes [156]
pVax-N3-NS5b NS3, NS4, NS5b Gt1b, Gt3a mice N/A yes yes [157]
* N/A (not applicable) for vaccine candidates that are not designed to elicit HCV-specific B cell responses. † N.D (not determined) in the study.
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6. Conclusions
In the 30 years since the discovery of HCV, it has been apparent that this virus is highly complex
and presents a major public health challenge. Encouragingly, efforts toward a vaccine continue and
investigation into a range of approaches have yielded interesting results. The vast improvements in
in vitro analysis of HCV have greatly aided our understanding of how nAbs work, informing rational
vaccine design. In this review, we have highlighted the potential advantages of adopting reference
panels of patient-derived E1E2 sequences in order to assess vaccine candidates for their potential to
induce nAbs capable of targeting circulating HCV strains. Adopting this approach will provide a
more rigorous tool for evaluating the nAb response produced by novel HCV vaccine candidates a
characteristic that will likely be essential in a successful HCV vaccine.
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